NAMUR, BELGIUM–(Jan 9, 2014) –  VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, announced today it has been selected to present at the 2^nd annual MicroCapClub Invitational.

The presentation can be accessed at the following link: http://microcapclub.com/2014/01/microcapclub-invitational-volitionrx-vnrx/

“At MicroCapClub we have 147 experienced microcap investors discussing over 180 microcap companies in our members forum. We handpick several unique companies every year to showcase to the public,” said Ian Cassel, founder of MicroCapClub. “We have been following VolitionRx since it went public a couple years ago and believe the company is now at an interesting inflection point. If the company’s blood based cancer diagnostic platform is successfully validated through large clinical trials in 2014, it will be a game changer for the cancer arena and shareholders. Given the company’s current valuation compared to its peer group, we feel VolitionRx is worth following.”

“We have an exciting year coming up,” says Cameron Reynolds, CEO of VolitionRx. “On the clinical side, we expect to publish initial results from our first major 4,800-individual colorectal cancer diagnostic trial, and begin the application process for European CE regulatory approval. We also expect to book significant early revenue from our epigenetic Research Use Kits, which will assist the company in funding our ongoing trials.”

About MicroCapClub
Founded in 2011, MicroCapClub is an exclusive forum for experienced microcap investors focused on microcap companies (sub $300m market cap). MicroCapClub was created to be a platform for experienced microcap investors to share and discuss stock ideas. MicroCapClub’s mission is to foster the highest quality microcap investor Community, produce Educational content for investors, and promote better Leadership in the microcap arena. For more information, visit www.MicroCapClub.com.

About VolitionRx
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream — an indication that cancer is present.

VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests.

Visit Volition’s website http://www.volitionrx.com or connect with us via Twitter (VolitionRx and VNRXInvestors), LinkedIn or Facebook.

Contact information:
Media Contacts
Charlotte Reynolds
VolitionRx
E: charlotte.reynolds@volitionrx.com
T: +44 7952 177 498

Investor Contacts
Kirin M. Smith
Proactive Capital
E: mksmith@proactivecapital.com
T: +1 646 863 6519